Creating New and Better Biopharmaceuticals
PhaseBio is developing drugs to treat endocrine, metabolic
and cardiovascular diseases using elastin-like biopolymers
which have been shown to increase drug half-life
and bioavailability while reducing side effects and cost.
Partnering with us
PhaseBio is interested in developing its current pipeline with pharmaceutical partners and out-licensing applications of its technology.